Melanoma TrialFinder

For patients

Find a trial

Search our trial database to find available and relevant melanoma clinical trials for you

Find a trial

20 trials in 41 locations

RELATIVITY-098: A Study to Assess Adjuvant Immunotherapy with Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage 3-4 Melanoma

Currently, patients are given adjuvant treatment with nivolumab immunotherapy for one year after having their melanoma resected. This is to try to reduce the chance of the melanoma coming back after it has been completely removed by the surgery.This trial aims to investigate if the combination treatment of relatlimab and nivolumab is more effective than the current standard treatment of nivolumab monotherapy, at stopping melanoma from coming back after it has been resected.The trial [...]

Locations: Nottingham University Hospitals NHS Trust, The Beatson West of Scotland Cancer Centre, Churchill Hospital

NAVIGATE: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children with NTRK-fusion Positive Solid Tumours

The trial aims to investigate if larotrectinib is effective at treating solid tumours with an NTRK positive gene mutstion.The trial also aims to look at how well patients tolerate treatment with larotrectinib, for example, if they might experience any side effects. Larotrectinib is a treatment that has just been licensed to treat solid tumours with an NTRK gene mutation, including NTRK positive melanoma. It is known as a TRK inhibitor. These types of treatments [...]

Locations: University College London Hospitals NHS Foundation Trust (UCLH), Beatson West of Scotland Cancer Centre,

THETIS (ATX-ME-001): ATL001 in Patients with Metastatic or Recurrent Melanoma

The trial aims to investigate how safe ATL001 is when it is used to treat melanoma and if patients experience any adverse events with the treatment.The trial also aims to measure how effective ATL001 is for treating melanoma, and how well it works when given with high or low-dose interleukin-2 (Il-2) or in combination with nivolumab immunotherapy ATL001 is made up of cells taken from your own melanoma, known as clonal neoantigen reactive T [...]

Locations: University College London Hospital (UCLH), Cambridge University Hospitals NHS Foundation Trust, University Hospital Southampton, The Royal Marsden Hospital (LONDON), Guys and St Thomas's NHS Foundation Trust, Freeman Hospital, The Christie NHS Foundation Trust

DETECTION: Circulating Tumour DNA Guided Therapy for Stage 2B or 2C Melanoma After Surgical Resection

After patients have had their melanoma completely removed (resected) by surgery, currently, they are not given any drug treatment afterwards and doctors monitor them at regular intervals to ensure that their melanoma has not returned. This trial aims to investigate if Circulating Tumour DNA ( ctDNA ) can indicate at an earlier timepoint if melanoma is likely to return after it has been completely resected, than with current standard monitoring procedures and follow-up.The trial [...]

Locations: Churchill Hospital, Addenbrookes Hospital, Nottingham City Hospital, The Christie NHS Foundation Trust, The Beatson West of Scotland Cancer Centre

DANTE: Duration of Anti-PD1 therapy for melanoma

At the moment, clinicians aren’t sure how long to give PD-1 inhibitor treatment for to patients with advanced melanoma. The current practice is to treat for at least two years if the patient continues to benefit and can tolerate treatment. However, the treatment seems to make the most difference within the first year and there is evidence to suggest that the treatment could be as effective and cause fewer side effects if it [...]

Locations: This trial is no longer recruiting new patients

MISST: Melanoma Immunomodulation and Immune Responses of the Skin Study: A Translational Science Research Protocol

This study aims to better understand how genes as well as the immune system affect the development of melanoma. Researchers hope that the results could improve how melanoma is detected and also lead to the development of new treatments for melanoma.The early stages of melanoma can be treated effectively by using surgery to remove the melanoma, but no cure is available at the moment in more advanced melanoma. Doctors currently don’t know what causes [...]

Locations: Guy's and St Thomas' NHS Trust

MelMarT-II: Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

The trial aims to look at how long patients stay free from melanoma after different types of surgery to remove the disease. A wide local excision involves removing an extra "safety margin" of skin around the original melanoma site, to make sure that any remaining scattered melanoma tumour cells that may have been left behind after the first biopsy/surgery are removed. At the moment melanoma specialists don’t know the ideal width of excision [...]

Locations: Royal Cornwall Hospital, Cambridge University Hospitals NHS Trust, Guys and St Thomas' NHS Foundation Trust, North Bristol NHS Trust, Norfolk and Norwich University Hospital, Hull University Teaching Hospitals NHS Trust, Oxford University Hospitals NHS Foundation Trust, Nottingham University Hospitals NHS Trust, Queen Victoria Hospital NHS Foundation Trust, The Royal Marsden NHS Foundation Trust, St Helen's & Knowsley Hospitals Trust, St George's University Hospitals NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, Mid and South Essex NHS Trust, South Tees Hospitals NHS Foundation Trust of The James Cook University Hospital

MITRE: Microbiome Immunotherapy Toxicity and Response Evaluation

The MITRE study aims to investigate whether there is a gut microbiome ‘signature’ (pattern) which can predict which patients receiving immune checkpoint inhibitors are likely to respond to treatment.The study also aims find out whether there is a link between the gut microbiome and risk of severe side effects associated with immune checkpoint inhibitor treatment. Gut Microbiome: People have hundreds of thousands of different types of natural bacteria living in the gastrointestinal tract, which [...]

Locations: Weston Park Hospital, Addenbrookes, Cambridge University Hospitals NHS Trust, Bristol Haematology and Oncology Centre, Royal Cornwall Hospital, Somerset NHS Foundation Trust, Norfolk and Norwich University Hospitals, Royal United Hospital Bath, University Hospital Southampton, Royal Bournemouth Hospital, Leicester Royal Infirmary, Western General Hospital

MAAM Study: Microwave Ablation in Advanced Melanoma Study

This trial aims to investigate if Microwave ablation (MWA) can be used to destroy and remove cutaneous melanoma metastases and also if it can help to stimulate the body’s natural defence ( immune system ) to attack the melanoma cells.This trial also aims to look at how patients tolerate the MWA treatment, through questionnaires and asking the patient to write notes in a pain diary.Microwave ablation (MWA) is a process that creates heat from [...]

Locations: University Hospital Southampton

MoleGazer: MoleGazer Development Feasibility Study

Melanoma can often develop from moles that already exist on your skin. Currently dermatologists will aim to review and identify new and changing moles in patients who have lots of moles on their body by using total body photography.Total body photography (TBP) is a method of taking high-quality photographs of a patient’s entire skin, so that doctors can track, compare and monitor moles over time. This has been shown to improve melanoma diagnosis.TBP is [...]

Locations: Churchill Hospital

ARTISTRY-6: Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma

The trial aims to investigate how effective nemvaleukin alfa is at treating unresectable and/or metastatic melanoma in patients who have previously received immunotherapy treatment with a PD-1 inhibitor for their melanoma.The trial also aims to look at how well patients cope with the treatment, for example, if they experience any side effects.The researchers also want to see if there is any difference to how well the drug works if the nemvaleukin alfa is given [...]

Locations: The Christie NHS Foundation Trust, Oxford University Hospitals NHS Foundation Trust

PECan: PDL1 Expression in Cancer

In this study, researchers want to find out if using 99mTc-labelled PD-L1 SPECT (see below for explanation) in melanoma patients, can help to predict how effective PD-1 inhibitor immunotherapy treatment will be to treat their melanoma. Usual standard scans will be carried out as well, so that the researchers can compare the two against each other.Currently, to see how well treatment is working for a melanoma patient doctors will use standard external (non-invasive) scans, [...]

Locations: Guy's and St Thomas' NHS Trust

The SCOPE Study: SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab

The trial aims to investigate if SCIB1 can be used safely as a combination treatment with current standard immunotherapy treatments, either nivolumab with ipilimumab or pembrolizumab.The trial also wants to look at how effective the combination treatment is at treating melanoma.Pembrolizumab is a standard immunotherapy treatment that is already used to treat different stages of melanoma. It stimulates the body’s natural defence ( immune system ) to attack and kill cancer cells.Nivolumab is a [...]

Locations: Churchill Hospital, Oxford University NHS Trust, Weston Park Hospital, Velindre University NHS Trust, Nottingham University Hospitals NHS Trust, Mount Vernon Hospital, East and North Hertfordshire NHS Trust

IGNYTE: Study of RP1 Monotherapy and RP1 in Combination with Nivolumab

In the phase 1 part of the trial, the aim was to investigate the safest dose of the experimental treatment; RP1, that patients can receive. Researchers then explored the safest dose of RP1 in combination with nivolumab, a PD1-inhibitor.Once the researchers have decided the safest doses, the phase 2 of the trial will look at how effective RP1, as a combination treatment with nivolumab, is at treating all types of melanomas, as well as [...]

Locations: University Hospital Southampton, St James's University Hospital, The Royal Marsden Hospital (LONDON), Churchill Hospital, The Clatterbridge Cancer Centre NHS Foundation Trust, Beatson West of Scotland Cancer Center

TebeMRD: Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma

This trial aims to look at how to treat patients with resected cutaneous melanoma who are thought to have a medium or high risk of the melanoma coming back, or patients with a diagnosis of uveal melanoma.This research will use a new blood test to see if there are any tiny amounts of melanoma cells in the body, which wouldn’t normally be seen on standard CT scans. This blood test can help doctors decide [...]

Locations: Churchill Hospital

TEBENTAFUSP: Tebentafusp Managed Access Program for Metastatic Uveal Melanoma

Uveal melanoma is generally treated with either chemotherapy or drugs that work by activating the body’s natural defence ( immune system ), known as immunotherapy. Some melanomas can avoid being seen or detected by the patient's own immune system, so that they can’t be attacked or killed. Immunotherapy works by stimulating the immune system to work against the melanoma by turning on or turning off certain signals in the immune system, to allow the [...]

Locations: The Beatson West of Scotland Cancer Centre, Norfolk and Norwich University Hospital, Belfast City Hospital, The Royal Marsden (LONDON), Royal Preston Hospital, University Hospital Birmingham, Nottingham City Hospital, Poole Hospital, Cheltenham General Hospital, East and North Hertfordshire NHS Trust, Castle Hill Hospital, Bristol Haematology and Oncology Centre, The Christie NHS Foundation Trust, The Freeman Hospital, Royal Cornwall Hospital, The Clatterbridge Cancer Centre - LIVERPOOL

IMP-MEL: Testing IMM60 in combination with pembrolizumab in melanoma and non-small cell lung cancer

The phase 1 of this trial aims to look at how safe the experimental treatment IMM60 is when it is given to patients. Researchers will look at how well patients cope with the treatment at different doses and if they experience any side effects. Once the safe dose of IMM60 is known it will be given to patients as a combination treatment with pembrolizumab, an immunotherapy drug that is already used in the treatment [...]

Locations: John Radcliffe Hospital

OOB: The Liverpool Ocular Oncology Biobank

The Liverpool Ocular Oncology Biobank (OOB) works closely with local and regional hospitals in the UK to collect and store ocular biosamples, blood and associated clinical data from consenting patients for use in research relating to eye cancers and other eye diseases. Biosamples are small parts of tissue that are removed from the ocular tumour so that doctors or researchers can analyse them.The biobank aims to build a valuable collection that will be used [...]

Locations: The Liverpool Ocular Oncology Centre

BNT111-01: Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage 3 or 4 Melanoma

This trial aims to investigate how effective the combination therapy of BNT111 and cemiplimab is at treating patients with stage 3 or stage 4 cutaneous melanoma who have previously had PD-1 inhibitor immunotherapy treatment, but it hasn’t worked.The trial will also look at how well patients cope with the combination treatment, for example, if they experience any side effects.BNT111 is an experimental therapeutic cancer vaccine. Therapeutic cancer vaccines aim to stimulate the body’s natural [...]

Locations: Royal Cornwall Hospital

INITIUM STUDY: UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Currently the first line treatment for patients that have unresectable melanoma is with immunotherapy. This trial aims to investigate if the use of UV1 vaccination in combination with ipilimumab and nivolumab immunotherapy is more effective at treating unresectable stage 3B,3C, 3D or 4 cutaneous melanomas than treating with immunotherapy alone, which is the current standard therapy.The trial also wants to look at how well patients tolerate the UV1 vaccination in combination with ipilimumab and [...]

Locations: The Christie NHS Foundation Trust